BioCardia (BCDA) said Monday its two-year phase 3 trial of its CardiAMP cell therapy to treat ischemic heart failure in patients with reduced ejection fraction reached no 'statistical significance' in its primary composite efficacy endpoint.
The double-blind randomized placebo-controlled trial, which involved 115 ischemic heart failure patients with reduced ejection fraction, maintained the patients on heart failure medication, while those treated with the CardiAMP minimally invasive cell therapy received a single dose adjunctive to medication.
The company said the trial results indicated increased survival and reduced major adverse cardiac and cerebrovascular events were observed throughout the study.
The company said it would share trial data with the US Food and Drug Administration and Japan's Pharmaceuticals and Medical Devices Agency to make the therapy available for physicians "as soon as possible."
Price: 2.55, Change: -0.25, Percent Change: -8.93
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。